Altrubio Inc.
Clinical trials sponsored by Altrubio Inc., explained in plain language.
-
New hope for tough ulcerative colitis cases? experimental drug ALTB-268 enters phase 2 trial
Disease control OngoingThis Phase 2a trial is testing an injectable biologic drug called ALTB-268 in 50 adults with moderately to severely active ulcerative colitis that has not improved with other biologic therapies. The study is open-label, meaning everyone receives the drug, and will measure changes…
Phase: PHASE2 • Sponsor: AltruBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New antibody ALTB-268 enters human testing for ulcerative colitis
Disease control OngoingThis early-stage trial tests a new drug called ALTB-268, a monoclonal antibody, in 24 healthy volunteers. The main goal is to check safety and how the body processes the drug. If it passes safety checks, it may later be tested in people with ulcerative colitis to see if it can co…
Phase: PHASE1 • Sponsor: AltruBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC